Company Description
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide.
The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures.
The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert.
In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure.
Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers.
The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001.
Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 1945 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 25,942 |
| CEO | David Endicott |
Contact Details
Address: Chemin de Blandonnet 8, Vernier Geneva, 1214 Switzerland | |
| Phone | 41 589 112 110 |
| Website | alcon.com |
Stock Details
| Ticker Symbol | ALC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001167379 |
| CUSIP Number | H01301128 |
| ISIN Number | CH0432492467 |
| Employer ID | 98-0205094 |
| SIC Code | 3851 |
Key Executives
| Name | Position |
|---|---|
| David J. Endicott | Chief Executive Officer and Director |
| Timothy C. Stonesifer | Senior Vice President and Chief Financial Officer |
| Ian Bell | Senior Vice President and Chief Operating Officer |
| Margaret Buckley | Chief Accounting Officer |
| Dr. Franck Leveiller Ph.D. | SVice President of Global Research and Development and Chief Scientific Officer |
| Muru Murugappan | Senior Vice President and Chief Information and Transformation Officer |
| Royce R. Bedward J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Leon Sergio Duplan Fraustro | Senior Vice President and President of Americas |
| Laurent Attias | Senior Vice President of Corporate Strategy, Business Development and Licensing (BD&L), M&A |
| Heather Attra | Senior Vice President and Chief Quality and Regulatory Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 144 | Filing |
| Feb 26, 2026 | 144 | Filing |
| Feb 24, 2026 | 6-K | Report of foreign issuer |
| Feb 24, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Feb 24, 2026 | 6-K | Report of foreign issuer |
| Jan 7, 2026 | 6-K | Report of foreign issuer |
| Nov 12, 2025 | 6-K | Report of foreign issuer |
| Aug 19, 2025 | 6-K | Report of foreign issuer |
| Aug 5, 2025 | DEFM14A | Filing |
| Aug 5, 2025 | 6-K | Report of foreign issuer |